ProKidney Corp operates as a biotech company. The Company develops therapies that repairs and restores diseased kidneys using a patient's own cells and may prevent or delay dialysis or transplant. ProKidney serves customers worldwide.

Current Report (Form 8-K | Period ending 2024-11-20)

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

ProKidney (PROK US)

Current Report (Form 8-K | Period ending 2024-11-20)

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Current Report (Form 8-K | Period ending 2024-09-03)

Quarterly Report (Form 10-Q | Period ending 2024-06-30)

Current Report (Form 8-K | Period ending 2024-08-09)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)